Immunome, Inc. Forecasted to Post FY2022 Earnings of ($3.18) Per Share (NASDAQ:IMNM)

Immunome, Inc. (NASDAQ:IMNMGet Rating) – Equities researchers at Cantor Fitzgerald upped their FY2022 EPS estimates for shares of Immunome in a note issued to investors on Tuesday, November 22nd. Cantor Fitzgerald analyst P. Stavropoulos now expects that the company will post earnings per share of ($3.18) for the year, up from their prior forecast of ($3.25). The consensus estimate for Immunome’s current full-year earnings is ($3.11) per share. Cantor Fitzgerald also issued estimates for Immunome’s FY2023 earnings at ($1.64) EPS.

Immunome Stock Performance

Shares of IMNM stock opened at $3.53 on Thursday. The stock’s fifty day moving average is $4.35 and its two-hundred day moving average is $4.15. The firm has a market capitalization of $42.76 million, a P/E ratio of -1.13 and a beta of 0.46. Immunome has a fifty-two week low of $2.09 and a fifty-two week high of $19.65.

Institutional Trading of Immunome

Hedge funds and other institutional investors have recently modified their holdings of the business. Renaissance Technologies LLC acquired a new position in Immunome in the 1st quarter valued at about $80,000. First Republic Investment Management Inc. purchased a new stake in Immunome in the first quarter valued at approximately $87,000. UBS Group AG lifted its stake in Immunome by 1,049.9% in the third quarter. UBS Group AG now owns 15,271 shares of the company’s stock valued at $68,000 after buying an additional 13,943 shares during the last quarter. Finally, Vanguard Group Inc. increased its holdings in shares of Immunome by 0.8% in the third quarter. Vanguard Group Inc. now owns 373,685 shares of the company’s stock valued at $1,659,000 after purchasing an additional 3,149 shares during the period. 19.86% of the stock is owned by institutional investors and hedge funds.

Immunome Company Profile

(Get Rating)

Immunome, Inc, a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19.

Recommended Stories

Receive News & Ratings for Immunome Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunome and related companies with's FREE daily email newsletter.